CS-1008 + Paclitaxel + Carboplatin

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer Stage IIIC

Conditions

Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV

Trial Timeline

Oct 6, 2009 → Aug 23, 2011

About CS-1008 + Paclitaxel + Carboplatin

CS-1008 + Paclitaxel + Carboplatin is a phase 2 stage product being developed by Daiichi Sankyo for Ovarian Cancer Stage IIIC. The current trial status is completed. This product is registered under clinical trial identifier NCT00945191. Target conditions include Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00945191Phase 2Completed

Competing Products

20 competing products in Ovarian Cancer Stage IIIC

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
33
pemetrexed + topotecanEli LillyPhase 1
33
arzoxifene hydrochlorideEli LillyPhase 2
52
LY4337713Eli LillyPhase 1
33
PrexasertibEli LillyPhase 2
52
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
44
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
52
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
41
Enzalutamide 40 MGAstellas PharmaPhase 2
52
ASP0739Astellas PharmaPhase 1/2
41
IMAB027Astellas PharmaPhase 1
33
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
52
Triptorelin for Injection + Recombinant Human Choriogonadotropin alfa Solution for Injection + Progesterone Soft CapsulesSun PharmaceuticalPhase 3
77
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52